抑制T细胞CDK9对TLR5靶向监测同种异体移植排斥的影响

doi:10.6040/j.issn.1671-7554.0.2017.981

摘要/Abstract

摘要： 目的探讨抑制T细胞中的细胞周期蛋白依赖性激酶9(CDK9)对Toll样受体5(TLR5)靶向监测同种异体移植急性排斥的影响。方法 Iodogen法碘化标记抗TLR5抗体(¹²⁵I-anti-TLR5),体外实验分析特异性及稳定性,脾细胞与¹²⁵I-anti-TLR5结合及解离实验分析脾细胞与标记物的亲和力;构建C57BL/6 -SCID小鼠T细胞介导同种异体移植急性排斥模型,LDC000067(CDK9抑制剂)(5 μmol/L)或等量PBS处理BALB/c小鼠T细胞并过继转输至模型小鼠,分为对照组(n=14)、抑制组(n=16),另有抑制组小鼠在注射¹²⁵I-anti-TLR5之前注射未标记抗TLR5抗体(10 mg/kg)为阻断组。观察抑制T细胞CDK9对同种异体移植物生存期影响及局部病理学改变;于对照组排斥高峰期时,对照组和抑制组小鼠尾静脉注射¹²⁵I-anti-TLR5,分析生物学分布、动态全身磷屏自显影显像及标记物的TLR5靶向性。结果抑制组移植皮片生存期(28.20±2.77)d,而对照组为(20.00±1.58)d;炎性浸润明显减少,TLR5表达增加。制备的¹²⁵I-anti-TLR5标记率达96.2%,体外稳定性良好(72 h仍保持在90%以上)。CDK9抑制剂体外处理后,受体鼠脾细胞与标记物的结合率增加,解离率降低(P均<0.05)。体内生物学分布研究表明,标记物主要经肝肾代谢,移植皮片放射性浓聚明显,抑制组72 h靶/非靶比值(3.70±0.16)较对照组(2.02±0.06)增高(P<0.05)。全身磷屏放射自显影结果显示,注射后48 h移植皮片显影,抑制组较对照组显像明显,且放射性浓聚持续时间长,阻断组未见明显放射性浓聚。结论抑制T细胞CDK9可明显延长同种异体移植物生存期,促进¹²⁵I-anti-TLR5同种异体移植物局部浓聚,有利于体内TLR5靶向同种异体移植急性排斥监测。

关键词: 放射性碘125, Toll样受体5, 细胞周期蛋白依赖性激酶9, 磷屏自显影显像, 同种异体移植

Abstract: Objective To explore the impact of T cells Cyclin-dependent kinase 9(CDK9)inhibition on Toll-like receptor 5(TLR5)targeting monitoring of acute allorejection. Methods ¹²⁵I-anti-TLR5 was prepared with Iodogen method. Label rate, stability and cell uptake and dissociation between spleen cells and ¹²⁵I-anti-TLR5 were analyzed. Allografted-SCID mouse models were established through T cells adoptive transferred and were divided into control group and CDK9 inhibition group. Another group of mice were injected with ¹²⁵I-anti-TLR5 before injection of unlabeled anti-TLR5 antibody(100 μL 10 mg/kg body weight)as a blocking group. Allograft survival and graft histopathology were observed. ¹²⁵I-anti-TLR5 was injected through tail vein at the peak of the control group rejection, and the biodistribution and whole-body phosphor-autoradiography were analyzed. Results T cells CDK9 inhibition apparently prolonged allograft survival from(20.00±1.58)d to(28.20±2.77)d, and weaken inflammation and increased expression of TLR5 on allografts. ¹²⁵I-anti-TLR5 was prepared successfully with high label rate(96.2%)and stability(>90% at 72 h). 山东大学学报 (医学版)56卷7期 -李晓梅,等.抑制T细胞CDK9对TLR5靶向监测同种异体移植排斥的影响 \=-Recipient spleen cells-pretreated with CDK9 inhibitor increased the uptake ratio of ¹²⁵I-anti-TLR5 and reduced the dissociating ratio(P<0.05). Ex vivo biodistribution studies revealed that ¹²⁵I-anti-TLR5 could be accumulated in skin allograft. T/NT ratio(allograft/ oposite skin)of CDK9 inhibition group was higher than that of control group(3.70±0.16 vs 2.02±0.06)at 72 h post injection. Whole-body phosphor-autoradiography imaging showed that clear graft localization was developed at 48 h, lasting longer in CDK9 inhibition group than control group, and no obvious accumulating imaging was noted in blocked group. Conclusion The inhibition of CDK9 on T cells can prolong allograft survival through reducing inflammation and promoting the expression of TLR5 of allograft, which may favor in vivo monitoring of TLR5 targeting acute allorejection.

Key words: Iodine 125, Toll-like receptor 5, Cyclin-dependent kinase 9, Phosphor auto-radio imaging, Allotransplantation

中图分类号:

R817.33

李晓梅,梁婷,张超,曹慧,侯桂华. 抑制T细胞CDK9对TLR5靶向监测同种异体移植排斥的影响[J]. 山东大学学报 (医学版), 2018, 56(7): 1-6.

LI Xiaomei, LIANG Ting, ZHANG Chao, CAO Hui, HOU Guihua. Impact of CDK9 inhibition for T cells on TLR5-targeting monitoring during allorejection[J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 1-6.

参考文献

[1] Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney[J]. Am J Transplant, 2014, 14(S1): 11-44.
[2] Sivanathan KN, Gronthos S, Rojas-Canales D, et al. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation[J]. Stem Cell Rev, 2014, 10(3): 351-375.
[3] Huynh A, Zhang R, Turka LA. Signals and pathways controlling regulatory T cells[J]. Immunol Rev, 2014, 258(1): 117-131.
[4] Griesemer A, Yamada K, Sykes M. Xenotransplantation: immunological hurdles and progress toward tolerance[J]. Immunol Rev, 2014, 258(1): 241-258.
[5] Scalea J, Hanecamp I, Robson SC, et al. T-cell-mediated immunological barriers to xenotransplantation[J]. Xenotransplantation, 2012, 19(1): 23-30.
[6] Satyananda V, Hara H, Ezzelarab MB, et al. New concepts of immune modulation in xenotransplantation[J]. Transplantation, 2013, 96(11): 937-945.
[7] Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells[J] , J Exp Med, 2006, 203(7): 1701-1711.
[8] Sun H, Yang G, Liang T, et al. Non-invasive imaging of allogeneic transplanted skin graft by 131 I-anti-TLR5 mAb[J]. J Cell Mol Med, 2014, 18(12): 2437-2444.
[9] Sheen JH, Heeger PS. Effects of complement activation on allograft injury[J]. Curr Opin Organ Transplant, 2015, 20(4): 468-475.
[10] Krystof V, Baumli S, Fürst R. Perspective of cyclin-dependent kinase 9(CDK9)as a drug target[J]. Curr Pharm Des, 2012, 18(20): 2883-2890.
[11] Schmerwitz UK, Sass G, Khandoga AG, et al. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9[J]. Arterioscler Thromb Vasc Biol, 2011, 31(2): 280-288.
[12] Zhan Y, Han Y, Hou G, et al. Down-regulating cyclin-dependent kinase 9 of alloreactive CD4 +T cells prolongs allograft survival[J]. Oncotarget, 2016, 7(18): 24983-24994.
[13] Valujskikh A, Matesic D, Gilliam A, et al. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice[J]. J Clin Invest, 1998, 101(6): 1398-1407.
[14] Duyveman AM, Kohno M, Duda DG, et al. A transient parabiosis skin transplantation model in mice[J]. Nat Protoc, 2012, 7(4): 763-770.
[15] Hricik DE,Poggio ED,Woodside KJ,et al. Effects of cellular sensitization and donor age on acute rejection and graft function after deceased-donor kidney transplantation[J]. Transplantation,2013, 95(10):1254-1258.
[16] 薛莹,张超,梁婷,等.¹²⁵I-rFlic及125I-rFlicΔ180-400 的制备及其在同种移植排斥监测中的作用[J]. 山东大学学报(医学版),2016,54(10):34-39. XUE Ying, ZHANG Chao, LIANG Ting, et al. Preparation and evaluation of ¹²⁵I-rFlic and 125I-rFlicΔ180-400 noninvasive radioimaging of allorejection[J]. Journal of Shandong University(Health Sciences), 2016, 54(10): 34-39.
[17] 金晶, 张海婧, 汪小涧,等. 新型免疫抑制剂SYL934的抗皮肤移植排斥反应研究[J]. 中国药理学通报, 2014, 30(6): 769-773. JIN Jing, ZHANG Haijing, WANG Xiaojian, et al. Anti-rejection study in mice skin transplantation of a novel immunosuppressant SYL934[J]. Chinese Pharmacological Bulletin, 2014, 30(6): 769-773.
[18] Jasiak NM, Park JM. Immunosuppression in solid-organ transplantation: essentials and practical tips[J]. Crit Care Nurs Q, 2016, 39(3): 227-240.
[19] Liou LY, Herrmann CH, Rice AP. Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function[J]. J Virol, 2002, 76(21): 10579-10587.
[20] Baumli S, Hole AJ, Noble ME, et al. The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508[J]. ACS Chem Biol, 2012, 7(5): 811-816.
[21] Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologicmalignancies[J]. Expert Opin Investig Drugs, 2013, 22(6): 723-738.
[22] Yik JH, Hu Z, Kumari R, et al. Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokines[J]. Arthritis Rheumatology, 2014, 66(6): 1537-1546.
[23] Sigdel TK, Gao X, Sarwal MM. Protein and peptide biomarkers in organ transplantation[J]. Biomark Med, 2012, 6(3): 259-271.
[24] Kawasaki T, Kawai T. Toll-like receptor signaling pathways[J]. Front Immunol, 2014, 5: 461. doi: 10.3389/fimmu.2014.00461.
[25] Carvalho FA, Aitken JD, Gewirtz AT, et al. TLR5 activation induces secretory interleukin-1 receptor antagonist(sIL-1Ra)and reduces inflammasome-associated tissue damage[J]. Mucosal Immunol, 2011, 4(1): 102-111.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed